194 studies found for:    "Anemia, Refractory"
Show Display Options
Rank Status Study
1 Completed Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Conditions: Blastic Phase Chronic Myelogenous Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Relapsing Chronic Myelogenous Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: alvocidib;   Drug: vorinostat
2 Completed
Has Results
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Biological: filgrastim;   Biological: sargramostim;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: zosuquidar trihydrochloride;   Drug: Placebo
3 Unknown  Bowel Preparation and Prokinetics in Capsule Endoscopy
Conditions: Small Bowel Disease;   Gastrointestinal Hemorrhage;   Refractory Anemia
Interventions: Drug: Senna;   Drug: Citramag powder;   Drug: Metoclopramide
4 Completed
Has Results
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Conditions: Acute Lymphoid Leukemia;   Acute Myeloid Leukemia;   Anemia, Refractory, With Excess of Blasts;   Solid Tumors
Intervention: Drug: brentuximab vedotin
5 Completed Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Disorders;   Anemia, Refractory, With Excess of Blasts
Intervention: Drug: Hum-195/rGel
6 Active, not recruiting Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T
Conditions: De Novo Akute Myeloid Leukemia (AML);   Secondary Acute Myeloid Leukemia (AML);   Refractory Anemia With Excess of Blasts in Transformation
Interventions: Drug: Cytarabine;   Drug: Idarubicin;   Drug: Etoposide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Daunorubicine
7 Completed Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: gemtuzumab ozogamicin
8 Terminated Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Conditions: Acute Myeloid Leukemia (AML);   Acute Promyelocytic Leukemia (APL);   Refractory Anemia With Excess of Blasts (RAEB)
Intervention:
9 Terminated Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
Intervention: Biological: GM-K562/leukemia cell vaccine
10 Recruiting Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Conditions: Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
Interventions: Drug: rigosertib;   Drug: Any approved or standard-of-care therapy;   Drug: best supportive care (BSC)
11 Active, not recruiting Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Conditions: Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Chronic Myelomonocytic Leukemia;   Cytopenia
Intervention: Drug: rigosertib sodium
12 Completed Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Conditions: Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation
Interventions: Drug: liposomal daunorubicin citrate;   Drug: semaxanib;   Other: laboratory biomarker analysis
13 Recruiting Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias
Conditions: Angiodysplasia;   Vascular Malformations;   Gastrointestinal Hemorrhage;   Anemia
Intervention: Drug: Octreotide
14 Terminated A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.
Condition: Acute Myeloid Leukemia
Interventions: Procedure: Two post-remission strategies;   Drug: Idarubicin versus daunorubicin
15 Completed Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
Conditions: Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Myelodysplastic Syndromes;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: lenalidomide
16 Completed Thalidomide in Treating Patients With Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
17 Completed Tipifarnib in Treating Patients With Myelodysplastic Syndromes
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia
Interventions: Drug: tipifarnib;   Other: laboratory biomarker analysis;   Other: pharmacological study
18 Unknown  Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant
Conditions: AML;   ALL;   Undifferentiated Leukemia;   Biphenotypic Leukemia;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts;   Refractory Anemia With Excess Blasts-1 (5-10% Blasts);   Refractory Anemia With Excess Blasts-2 (10-20% Blasts);   Myelodysplastic Syndrome, Unclassified;   MDS Associated With Isolated Del (5q)
Intervention: Drug: Abatacept
19 Completed Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Fanconi Anemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Intervention: Other: laboratory biomarker analysis
20 Completed Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Conditions: Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Drug: therapeutic hydrocortisone;   Procedure: allogeneic bone marrow transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Biological: filgrastim;   Drug: cytarabine;   Drug: idarubicin;   Drug: dexamethasone;   Drug: thioguanine;   Drug: etoposide;   Drug: methotrexate;   Drug: cyclophosphamide;   Biological: aldesleukin;   Drug: busulfan

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.